Department of Clinical Dermatology, Centre for the Study and Treatment of Psoriasis, San Gallicano Dermatological Institute, IRCCS, Rome, Italy.
Scientific Direction, San Gallicano Dermatological Institute, IRCCS, Rome, Italy.
Dermatol Ther. 2019 May;32(3):e12909. doi: 10.1111/dth.12909. Epub 2019 Apr 23.
Treatment of severe psoriasis (PsO) in organ transplant (OT) patients is difficult. In fact, systemic drugs used for PsO therapy can be detrimental to transplanted organs and/or can increase the risk of serious infections in subjects already taking antireject medicines. Current guidelines fail to give indications on how to manage PsO OT subjects. Moreover, only a few cases of patients with the above-cited characteristics treated with systemic therapies have been published so far. Here, we report our experience concerning a liver transplant patient successfully treated with ixekizumab for his psoriasis throughout 1 year.
治疗器官移植（OT）患者的严重银屑病（PsO）较为困难。实际上，用于 PsO 治疗的全身药物可能对移植器官有害，/并且/或者会增加已经服用抗排斥药物的受试者发生严重感染的风险。目前的指南没有说明如何管理 OT 患者的 PsO。此外，迄今为止，/只有/少数患有上述特征的患者接受全身治疗的病例被报道。在这里，我们报告了 1 例肝移植患者的经验，/他/使用依奇珠单抗成功治疗了 1 年的银屑病。
